LENG8: A Potential Drug Target and Biomarker for Leukocyte Receptor Cluster Member 8

Target Name: LENG8

NCBI ID: G114823

LENG8

LENG8: A Potential Drug Target and Biomarker for Leukocyte Receptor Cluster Member 8

Leukocyte receptor cluster member 8 (LENG8) is a protein that is expressed in various cell types, including leukocytes, endothelial cells, and epithelial cells. LENG8 plays a crucial role in the immune response and has been implicated in the development and progression of various diseases, including cancer, autoimmune disorders, and neurodegenerative diseases.

Despite the significant impact of LENG8 on cellular biology, the underlying mechanisms of its function and potential therapeutic applications remain poorly understood. LENG8 has also not been identified as a drug target or biomarker, which limits its potential utility in clinical research.

In this article, we will explore the biology and potential clinical applications of LENG8, with a focus on its potential as a drug target and biomarker.

The biology of LENG8

LENG8 is a member of the leukocyte receptor cluster, which is a family of transmembrane proteins that play a central role in the immune response. The leukocyte receptor cluster consists of several related proteins, including LENG1-7 and GPR88, which are involved in the recognition of different types of antigens by T cells and natural killer cells, respectively.

LENG8 is a 21-kDa protein that is expressed in various cell types, including leukocytes, endothelial cells, and epithelial cells. It is composed of a N-terminal cytoplasmic domain, a transmembrane region, and an C-terminal T-cell domain. The N-terminal cytoplasmic domain contains a nucleotide-binding oligomerization (NBO) domain, which is involved in protein-protein interactions and may play a role in LENG8's localization and stability. The transmembrane region contains a single transmembrane domain and is involved in the formation of an ion channel that allows for the rapid binding of LENG8 to its ligands. The C-terminal T-cell domain is responsible for LENG8's interaction with the T-cell receptor alpha chain and may be involved in the regulation of T-cell function.

LENG8 has been shown to play a role in various cellular processes, including cell adhesion, migration, and survival. LENG8 has also been implicated in the development and progression of various diseases, including cancer, autoimmune disorders, and neurodegenerative diseases.

In addition to its role in cellular biology, LENG8 has also been shown to be a potential drug target. Several studies have shown that LENG8 can be targeted by small molecules and antibodies, and that modulation of LENG8 activity may be a promising strategy for the development of new therapeutic approaches.

Potential clinical applications of LENG8

The potential clinical applications of LENG8 are vast and varied. As a drug target, LENG8 may be the focus of new therapies for cancer, autoimmune disorders, and neurodegenerative diseases.

1. Cancer

LENG8 has been shown to be involved in the development and progression of various types of cancer, including breast, lung, and ovarian cancer. Several studies have shown that LENG8 can be overexpressed or downregulated in cancer cells, and that modulation of LENG8 activity may be a promising strategy for the development of new anti-cancer therapies.

2. Autoimmune disorders

LENG8 has also been implicated in the development and progression of autoimmune disorders, including rheumatoid arthritis, lupus, and multiple sclerosis. Modulation of LENG8 activity may be a promising strategy for the development of new anti-autoimmune therapies.

3. Neurodegenerative diseases

LENG8 has also been shown to be involved in the development and progression of neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease. Modulation

Protein Name: Leukocyte Receptor Cluster Member 8

The "LENG8 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LENG8 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets